In 2025, the LISI Group posted organic growth of over 10% for the fourth consecutive year, with a significant increase in its financial results in line with its objectives

•  Published revenue (excluding medical) reached a record level of €1,747.9 million, up +8.7% compared to 2024¹, reflecting in particular the strong ramp-up in all segments of the aerospace market.

•  EBIT amounted to €161.0 million, up +63.2% compared to 2024. The current operating margin thus improved by +3.1 points to 9.2%.

•  Free Cash Flow is strongly positive in both of the Group's divisions, LISI AEROSPACE and LISI AUTOMOTIVE, at €56.1 million after net industrial investments of nearly €100.0 million.

•  The financial structure was strengthened with net financial debt falling to 0.9x EBITDA following the sale of the LISI MEDICAL division (compared to 2.3x in 2024).

Outlook:

•  The strength of the aerospace division's order book points to another year of growth for the Group in 2026.

•  Objective: to continue improving key financial indicators (particularly current operating income) and generate positive free cash flow in 2026, assuming constant exchange rates and macroeconomic conditions.

LISI AEROSPACE

•  Record revenue of €1,191.1 million (2024: €1,030.1 million), supported by strong activity across all segments of the aerospace market;

•  Current operating income of €140.1 million (2024: €85.7 million), up for the fourth consecutive year, driven by improved industrial productivity;

•  Free cash flow from operations at €61.5 million, up threefold compared to 2024 (€20.8 million in 2024), driven by improved recurring operating income and a gradual decline in inventory levels, particularly raw materials.

LISI AUTOMOTIVE

•  The division's revenue amounted to €558.5 million, down 3.7% compared to 2024, impacted by the decline in global production by the division's automotive manufacturer customers.

•  The current operating margin increased by two points compared to 2024 and stood at 5.0% of revenue.

•  Operating free cash flow was positive for the tenth consecutive year.

OUTLOOK

The LISI Group remains vigilant in the face of global geopolitical and macroeconomic uncertainties, particularly changes in customs policies and currency exchange rates.

The aerospace development plan is the Group's main growth driver, with excellent visibility over the long term. Furthermore, the persistent uncertainty surrounding developments in the global automotive market requires the automotive division to continue its efforts to lower its break-even point, which is already well advanced.

With its strengthened financial position, the Group is confident that it will be able to consolidate its position as the global leader in its chosen niche markets in the future. Its objective, assuming constant exchange rates and macroeconomic conditions, is to improve its key financial indicators, including current operating income, for the fourth consecutive financial year and to once again generate positive free cash flow.

1 Restated 2024 revenue for LISI MEDICAL equal to €1,608.7 million